Off the wire
ECB foreign exchange rates of Euro to other currencies  • French stock market index down 0.98 pct on Tuesday  • Austrian police strike major blow against family-run drug ring  • Roundup: Scientists in Italy discover "hiding place" of HIV virus in cells  • Chinese devices winning over visitors at Barcelona mobile congress  • 1st LD Writethru: Ex-CIA chief reaches plea deal over charge of mishandling classified information  • 2nd LD: Israeli PM calls for rejection of bad nuke deal with Iran  • African sprinters to compete for Kenya relay championships  • LME base metals decrease mostly on Tuesday  • Irish tax revenues 345 mln euros ahead of target by Feb.  
You are here:   Home

Cancer gene capable of slowing cancer growth: Austrian researchers

Xinhua, March 4, 2015 Adjust font size:

The suppression of the known cancer gene "STAT3" may actually be counter productive in the fight against some cancers, an international research team including two Austrian researchers found, local media reported Tuesday.

Beatrice Grabner and Emilio Casanova from the Ludwig Boltzmann Institute for Cancer Research in Vienna said the results of their study, published in the journal Nature Communications, show that particularly for smokers, the STAT3 gene can inhibit the growth and aggressiveness of tumors.

Researchers told the APA on Tuesday that the STAT3 gene can indeed drive tumor growth in some forms of lung cancer, and because of this, drugs are currently being developed to block its activity.

If, however, during the presence of lung tumors, another gene known as "KRAS" is changed in certain ways, STAT3 can play an "unexpected tumor-suppressive role."

Such changes to KRAS occur mainly in patients with a history of smoking, the researchers said.

In their research conducted on mice with lung tumor cells, the team also found an altered KRAS gene resulted in more aggressive growth of cancer tumors when the STAT3 gene was missing.

Additionally, they found a connection between smokers with lung cancer and low STAT3 activity, and advanced tumors along with a poor survival outlook.

Grabner said patients with a history of smoking should in no circumstances be treated with STAT3-suppressing drugs, though for non-smokers these would "probably make sense," she added. Endit